VIVS VivoSim Labs, INC.
Company Updates ·
Organovo, a VivoSim subsidiary, agreed on October 13, 2026 to vacate Suite 202 by February 28, 2027, extend Suite 100 through April 30, 2028 and receive a partial rent abatement.
At its September 30, 2026 annual meeting, VivoSim Labs stockholders elected Keith Murphy and Adam Stern and approved a reverse stock split range of 1-to-5 to 1-to-20.
Nasdaq staff said VivoSim Labs has until February 16, 2027 to show a closing bid price of at least $1 for ten consecutive business days, and the company is weighing a reverse split.
VivoSim Labs said Nasdaq told it on August 4, 2026 that it met the $2.5M stockholders' equity minimum, after a $5.0 million milestone payment, an escrow release and a $4.0 million financing in July.
Nasdaq said VivoSim Labs no longer met the $2,500,000 stockholders' equity minimum on July 20, 2026, and the company said its equity exceeded $2.5 million after July transactions.
VivoSim Labs agreed to sell 4,705,883 shares and warrants to one healthcare investor, with A.G.P./Alliance Global Partners as sole placement agent.
VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company that tests drugs and drug candidates in three-dimensional human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights using its new approach methodologies (NAM) models. The company expects accelerated adoption of human tissue models after the FDA's April 10, 2025 announcement to refine animal testing requirements. It also expects to offer bespoke services in investigational toxicology and mechanism of drug action elucidation. Before March 2025 it was a clinical stage biotechnology company focused on FXR314 in inflammatory bowel disease. In March 2025 it sold the FXR program for $10.0 million, with $9.0 million paid at closing and $1.0 million held in escrow, plus milestones of up to $50.0 million. In July 2026 it received a $5.0 million milestone payment related to FXR314. The company changed its name to VivoSim Labs, Inc. to reflect a business model that includes its 3D bioprinting IP. It presented findings at the May 2025 Digestive Disease Week conference showing that its liver platform had 87.5% sensitivity and 100% specificity.
| Product or program | What it is | Stage |
|---|---|---|
| Liver toxicology predictive screening (NAMkind liver) | 3D human liver tissue model for drug toxicology screening and research | Now offered |
| Intestinal toxicology models | 3D human intestinal models for predicting drug side effect profiles | |
| FXR314 | Candidate for inflammatory bowel disease, sold in March 2025 | Phase 2a in ulcerative colitis was planned for calendar 2025; program sold March 2025 |
| Line | FY ended Mar 31, 2026 | FY ended Mar 31, 2025 |
|---|---|---|
| Research and development | $4.2 million | $5.0 million |
| Net income (loss) | -$13.8 million | -$2.5 million |
| Cash from operations | -$10.8 million | -$9.5 million |
| Cash and equivalents | $5.0 million | $11.3 million |
Our latest story on this, dated Oct 6, 2026: "VivoSim Labs stockholders elect two directors and approve split range". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 16, 2026: "VivoSim Labs prices $4.0 million private placement with $0.85 warrants". The story links the filing or release it is based on. Read the story.
VivoSim Labs, INC. trades under the ticker VIVS on NASDAQ.
VivoSim Labs, INC. is listed on NASDAQ.
Our directory records VivoSim Labs, INC. under United States.
aibio.space lists VivoSim Labs, INC. among 2,820 public biotech companies and publishes its news here as stories appear.
VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company that tests drugs and drug candidates in three-dimensional human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights using its new approach methodologies (NAM) models.
Liver toxicology predictive screening (NAMkind liver): 3D human liver tissue model for drug toxicology screening and research Stage: Now offered.
Intestinal toxicology models: 3D human intestinal models for predicting drug side effect profiles Stage: Not stated in text.
VivoSim Labs, INC. reported a net loss of $13.8 million for the fiscal year ended Mar 31, 2026, and used $10.8 million of cash in operations, per its annual report to the SEC.
$4.2 million in the fiscal year ended Mar 31, 2026, per its annual report.
$1.7 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on VivoSim Labs, INC., dated Oct 16, 2026: "VivoSim amends Organovo lease, giving up part of its San Diego office". Organovo, a VivoSim subsidiary, agreed on October 13, 2026 to vacate Suite 202 by February 28, 2027, extend Suite 100 through April 30, 2028 and receive a partial rent abatement. Source.
Press Follow on this page to add VivoSim Labs, INC. to your Following list, or subscribe to the aibio.space newsletter. We have published 6 stories naming VivoSim Labs, INC. so far, in Company Updates, Financings, Listings.
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio